An interventional study of The Endogenex Device in Diabetes, Diabetes Type 2 and Diabetes Mellitus, Type 2, sponsored by Endogenex, Inc.. Completed at 3 sites in United States. Open to participants aged 22 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-22.
Sponsored by Endogenex, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States — 345 open to participants now, 479 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.
Among the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 2,493rd largest by enrollment of the 2,961 interventional ones that give a count, is one of 172 that started in 2021, is one of 1,242 with no phase, and was the 2,530th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →345 of the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Puerto Rico
Ages 18+
University of Minnesota · Sites in United States
Ages 30–75
Montefiore Medical Center · Sites in United States
Ages 18–85
Pfizer · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States, Singapore
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 22 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,308 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 425 · Phase 2 465 · Phase 3 613 · Phase 4 300
First in 1976; this study’s year is marked. 172 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 90 across the 2,961 interventional studies, 128 across the 336 observational. Of the 2,651 that completed or were terminated, 1,166 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
1,489 of 3,308 have an industry lead sponsor. The 10 most frequent:
Endogenex, Inc. is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
Endogenex, Inc. has 6 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
189 of the studies in Diabetes Mellitus, Type 2 with a site in United States that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06731075Phase 3Oramed, Ltd.A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus. | 2027-04-25 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07817251Phase 3Novo Nordisk A/SResearch Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | 2027-06-09 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
Add all 189 to your calendar (.ics) → With an account.
Among the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, open-label study to assess the feasibility and preliminary safety of the Endogenex Device for endoscopic duodenal mucosal regeneration in patients with type 2 Diabetes inadequately controlled on 2-3 non-insulin glucose-lowering medications.
Individuals who sign the informed consent will be screened for study eligibility. Eligible participants will be treated with the Endogenex procedure and followed up for 48 weeks.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
This study's enrollment of 20 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Endogenex, Inc. is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Critically ill or has a \<3 years
Additional exclusion criteria to be confirmed during the screening process:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All eligible patients will receive the endoscopic Endogenex procedure.
Device: The Endogenex Device
The Endogenex device is designed to induce duodenal mucosal regeneration using pulsed electric field. The Endogenex procedure is a non-surgical, endoscopic procedure.
Participants Experiencing Device- or Procedure-Related Serious Adverse Events (SAE)
Number of participants experiencing device- or procedure-related serious adverse events (SAE)
Time frame: 12 weeks post-procedure
Mean HbA1c by Follow-up Visit
Mean HbA1c by Post Procedure Follow-up Visits
Time frame: at 4,12, 24, and 48 Weeks Post Procedure
Mean Fasting Plasma Glucose (FPG) by Visit
Mean Fasting Plasma Glucose (FPG) at Post Procedure Follow-up Visit
Time frame: Follow-up at 4,12, 24, 36, and 48 weeks post procedure
Mean Weight by Follow-up Visit
Mean weight by Post Procedure Follow-up Visit
Time frame: Follow-up at 4,12, 24, 36, and 48 weeks post procedure
Procedural Success
Percentage of participants with successful DMR procedure
Time frame: At the time of procedure
Procedural Time
Time between catheter insertion to catheter removal
Time frame: At the time of procedure
Participants were recruited from 3 study sites in the US. Twenty participants were enrolled (i.e. received Endogenex treatment). Two participants did not complete the study due to patient withdrawal and physician withdrawal to relocation.
| Milestone | Interventional Arm- Endogenex (PEF) Treatment |
|---|---|
| Started | 20 |
| Completed | 18 |
| Not completed | 2 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Physician decision | 1 |
Number of participants experiencing device- or procedure-related serious adverse events (SAE)
| Number of Participants with related SAE | Interventional Arm- Endogenex (PEF) Treatment |
|---|---|
| Participants Experiencing Device- or Procedure-Related Serious Adverse Events (SAE) | 0 |
Mean HbA1c by Post Procedure Follow-up Visits
| HbA1c % | Interventional Arm- Endogenex (PEF) Treatment |
|---|---|
| Mean HbA1c at Week 4 Post Procedure | 7.2 ± 0.7 |
| Mean HbA1c at Week 12 Post Procedure | 6.7 ± 0.7 |
| Mean HbA1c at Week 24 Post Procedure | 6.9 ± 1.1 |
| Mean HbA1c at Week 36 Post Procedure | 7.0 ± 0.7 |
| Mean HbA1c at Week 48 Post Procedure | 7.2 ± 0.8 |
Mean Fasting Plasma Glucose (FPG) at Post Procedure Follow-up Visit
| mg/dL | Interventional Arm- Endogenex (PEF) Treatment |
|---|---|
| Mean FPG at Week 4 post procedure | 140.1 ± 28.6 |
| Mean FPG at Week 12 post procedure | 155.7 ± 28.8 |
| Mean FPG at Week 24 post procedure | 155.9 ± 42.7 |
| Mean FPG at Week 36 post procedure | 150.8 ± 24.2 |
| Mean FPG at Week 48 at post procedure | 161.6 ± 37.0 |
Mean weight by Post Procedure Follow-up Visit
| lbs | Interventional Arm- Endogenex (PEF) Treatment |
|---|---|
| Mean Weight at Week 4 Post Procedure | 215.6 ± 38.1 |
| Mean Weight at Week 12 Post Procedure | 209.3 ± 36.1 |
| Mean Weight at Week 24 Post Procedure | 214.9 ± 40.3 |
| Mean Weight at Week 36 Post Procedure | 213.3 ± 41.1 |
| Mean Weight at Week 48 Post Procedure | 217.8 ± 41.7 |
Percentage of participants with successful DMR procedure
| Participants | Interventional Arm- Endogenex (PEF) Treatment |
|---|---|
| Procedural Success | 20 |
Time between catheter insertion to catheter removal
| minutes | Interventional Arm- Endogenex (PEF) Treatment |
|---|---|
| Procedural Time | 82.9 ± 20.1 |
Collected over Enrollment through study completion at 48 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Interventional Arm- Endogenex (PEF) Treatment | 0/20 (0%) | 5/20 (25%) | 19/20 (95%) |
| Event | Interventional Arm- Endogenex (PEF) Treatment |
|---|---|
| NephrolithiasisRenal and urinary disorders | 1/20 |
| Acute cholecystitisHepatobiliary disorders | 1/20 |
| CholecystectomyHepatobiliary disorders | 1/20 |
| Malignant MelanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/20 |
| Colon AdenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/20 |
| Event | Interventional Arm- Endogenex (PEF) Treatment |
|---|---|
| Oropharyngeal PainGastrointestinal disorders | 14/20 |
| ConstipationGastrointestinal disorders | 4/20 |
| COVID-19Infections and infestations | 3/20 |
| Upper abdominal PainMusculoskeletal and connective tissue disorders | 2/20 |
| Back PainMusculoskeletal and connective tissue disorders | 2/20 |
| ConjunctivitisInfections and infestations | 2/20 |
| GastroenteritisGastrointestinal disorders | 2/20 |
| NasopharyngititisInfections and infestations | 2/20 |
| NauseaGastrointestinal disorders | 2/20 |
| EsophagititisGastrointestinal disorders | 2/20 |
| Age, Customized(years) | Interventional Arm- Endogenex (PEF) Treatment |
|---|---|
| Age | 54.4 ± 7.8 |
| Sex: Female, Male(Participants) | Interventional Arm- Endogenex (PEF) Treatment |
|---|---|
| Female | 5 |
| Male | 15 |
| Race (NIH/OMB)(Participants) | Interventional Arm- Endogenex (PEF) Treatment |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 20 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Ethnicity (NIH/OMB)(Participants) | Interventional Arm- Endogenex (PEF) Treatment |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 20 |
| Unknown or Not Reported | 0 |
| HbA1c (%)(%) | Interventional Arm- Endogenex (PEF) Treatment |
|---|---|
| Mean | 8.3 ± 0.54 |
| Duration of Diabetes (years)(years) | Interventional Arm- Endogenex (PEF) Treatment |
|---|---|
| Mean | 6.7 ± 2 |
| BMI (kg/m²)(kg/m²) | Interventional Arm- Endogenex (PEF) Treatment |
|---|---|
| Mean | 32.4 ± 4.3 |
| Weight (lbs)(lbs) | Interventional Arm- Endogenex (PEF) Treatment |
|---|---|
| Mean | 224 ± 39 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2021 to primary completion in May 2024, 31 months.
Results were first posted in Dec 2025, 1 year 6 months after primary completion.
Of 177 industry-sponsored interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 29. This study's 31 months is above that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Endogenex, Inc.